Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.
about
Allogeneic stem cell transplantation in first complete remissionAdvances in haplo-identical stem cell transplantation in adults with high-risk hematological malignanciesAlternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaWho is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative GrouEx vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation.T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCTSignificant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent eraReduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?Who is the best alternative allotransplant donor?Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMTPractice variation in physician referral for allogeneic hematopoietic cell transplantation.Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation ResearchBone marrow transplantation and acute myeloid leukemia: Brazilian guidelines.Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: the cost of freedom.Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Unfavorable-risk cytogenetics in acute myeloid leukemia.Upfront therapy of acute myeloid leukemia.Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia.Lenalidomide as a novel treatment of acute myeloid leukemia.Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: are we closer to knowing who needs it?Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective.Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors?Immunotherapy in acute myeloid leukemia.Allogeneic transplantation for CML in the TKI era: striking the right balance.Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients.Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry-based study.Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older.Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies.Unrelated bone marrow transplantation or immediate umbilical cord blood transplantation for patients with acute myeloid leukemia in first complete remission.Long-term clinical outcomes of hematopoietic cell transplantation for intermediate-to-poor-risk acute myeloid leukemia during first remission according to available donor types.Are alternative donors really still "alternative?".Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study.Outcomes of patients with therapy-related AML/myelodysplastic syndrome (t-AML/MDS) following hematopoietic cell transplantation.
P2860
Q26996818-79EDB796-1A10-4D83-861C-0F748FAD8A10Q27014857-702DC250-7D3D-473E-9FD6-0263F095210AQ28080943-C62C2394-5994-4C4C-B9AD-702B3261426EQ30414156-F4D757E6-FF3D-4193-98BB-8266A3B197A4Q31143348-6E327375-40C4-4BC6-BA97-2C3818C728E5Q33760933-D286C7F9-1676-4D81-A4C0-7333B177590BQ34273628-FD5B9156-DBF0-4756-B068-12B5E3039347Q34398411-5D81986D-8AEF-42E8-B29A-04F06EFAAF33Q34749365-58EB7AE6-5379-4A70-9AAC-0A41B5B86654Q35608181-846B8955-5355-4B98-879A-12EC772BB381Q35772737-E1EC1622-0159-466A-B3D6-39BE93D596A0Q35903721-BBF34B82-6428-4C8C-A82D-D5BBB22035ECQ36121885-4FBD041E-B3B4-428B-8BA2-BAC9C9276B1FQ36547170-C22DD068-23EB-459B-B5C0-3EB701F5C3EAQ36579065-7C65B915-E6FB-4AD8-93E5-D03F7FC19008Q36753274-3B5A5AE1-4C0B-466C-8B45-C6E10E561E12Q36788458-2330606F-9479-4A9E-8CA6-59BDC602D578Q36794295-B32CC26A-B0C6-4D56-9E6F-7B409445CBD3Q37079011-ECE18F6C-8A94-4CC7-A732-A449281E9187Q37517482-CC26E20A-E9A0-4CC8-8355-B22DFA0A7263Q37865545-9AE34597-9C35-4203-A4E7-7AF49ADF3354Q37897183-74DA1D50-9549-4290-B59E-45D83CCF5475Q38015268-1660FBFB-9AA5-431A-AC44-D73CE4B6761BQ38073811-E1068EA2-307A-426E-9514-10A879C60651Q38130168-89669923-A125-4ADA-AC03-9A0D2BD6AD2DQ38199056-A37AAFE9-AD3D-4D4C-9144-38F1AFD6F662Q38248427-2CDBF86A-0466-42D4-9861-9C296BEBE3C1Q38350274-A8BCB384-1A67-4767-8CD1-E9DCF17388C7Q38533606-894881F2-7B81-4F45-8151-DCB75A538F65Q38634736-3FABBEED-4DA1-44C7-98CC-472C33D9C9FFQ38657161-B538E227-E234-410A-98EA-DE3374DE6F26Q39002065-2060E8E1-0B13-450B-8F28-A0D458C833DBQ39005630-E3BCC4B7-0AA9-4B24-B94A-52392288EAE4Q39972636-D8CA3224-DD64-4F90-8772-5A493CC2D1BEQ40106226-B142B66B-3B88-4196-B23F-CBA4908C3F2CQ40199108-8CEAF7AF-7882-41CC-9451-13A2C7A0336BQ41092916-C40D986D-0114-48EB-B0AC-DEC2B1AE066CQ41185627-71C31921-7E27-4784-AAED-1692447D31EEQ41607636-7AE0FE93-2AFB-4308-810E-C0910AF378A0Q41632376-9B3A6CDA-7B16-4C37-B039-88A928FB5CD4
P2860
Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Comparable survival after HLA- ...... ble cytogenetics at diagnosis.
@ast
Comparable survival after HLA- ...... ble cytogenetics at diagnosis.
@en
Comparable survival after HLA- ...... ble cytogenetics at diagnosis.
@nl
type
label
Comparable survival after HLA- ...... ble cytogenetics at diagnosis.
@ast
Comparable survival after HLA- ...... ble cytogenetics at diagnosis.
@en
Comparable survival after HLA- ...... ble cytogenetics at diagnosis.
@nl
prefLabel
Comparable survival after HLA- ...... ble cytogenetics at diagnosis.
@ast
Comparable survival after HLA- ...... ble cytogenetics at diagnosis.
@en
Comparable survival after HLA- ...... ble cytogenetics at diagnosis.
@nl
P2093
P2860
P50
P1433
P1476
Comparable survival after HLA- ...... ble cytogenetics at diagnosis.
@en
P2093
Brent R Logan
Daniel J Weisdorf
David A Rizzieri
David I Marks
Donald W Bunjes
Edmund K Waller
Edward Copelan
Hanna J Khoury
Jacob M Rowe
John F DiPersio
P2860
P304
P356
10.1182/BLOOD-2010-04-278317
P407
P577
2010-06-10T00:00:00Z